Sydney, NSW – MEDISCA Australia is pleased to announce their new partnership with The National Institute of Complementary Medicine (NICM) at Western Sydney University. For the first time, Australian compounding pharmacists will have a local dedicated service for testing finished compounds.
The NICM provides the perfect partnership for MEDISCA through aligned rigorous quality procedures. Holding a TGA licence, Australian customers will enjoy peace of mind that their products will be tested to the highest Australian standards.
In the past, testing services in Australia have long been geared towards big pharma companies. However, with a dedicated and affordable solution specific to the needs of compounding pharmacists, MEDISCA customers can help grow their industry by ensuring continued quality improvement in their products. A number of tests will be available including:
Preservative Efficacy Tests
Total Plate Counts Tests
Bacterial Endotoxins Tests
Other Microbiology Tests
By providing their customers with access to a high-quality testing service located directly in Australia, MEDISCA customers will also save money on shipping and save valuable time by reducing the waiting period for results.
MEDISCA is the leader in providing turnkey solutions to the pharmaceutical compounding industry and allied health care professionals worldwide. Through its global partners, LP3 Network and MEDISCA Network, MEDISCA is committed to being a complete resource for prescribers, pharmacists and pharmacy technicians engaged in personalized medicine by offering educational trainings, products, and support. Founded in 1989, the company has locations in Canada, the United States and Australia, optimizing its service to the international market. For more information about MEDISCA, please visit www.medisca.com and follow us on Twitter at @medisca.